Nemolizumab
- Generic Name
- Nemolizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1476039-58-3
- Unique Ingredient Identifier
- GN465U8B72
- Background
Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 192
- Registration Number
- NCT05405985
- Locations
- 🇺🇸
Galderma Investigational Site 7024, Tempe, Arizona, United States
🇺🇸Galderma Investigational Site 7023, Lincoln, Nebraska, United States
An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05214794
- Locations
- 🇯🇵
The University of Tokyo Hospital, Tokyo, Japan
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
- Conditions
- Interventions
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 258
- Registration Number
- NCT05075408
- Locations
- 🇺🇸
Galderma Investigational Site 9965, Miami, Florida, United States
🇺🇸Galderma Investigational Site7016, Miami, Florida, United States
🇺🇸Galderma Investigational Site 9962, Las Vegas, Nevada, United States
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
- Conditions
- Interventions
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Galderma R&D
- Registration Number
- NCT05056779
A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 34
- Registration Number
- NCT05052983
- Locations
- 🇨ðŸ‡
Galderma Investigational Site 5069, Lausanne, Switzerland
🇵🇱Galderma Investigational Site 6237, Ostrowiec Świętokrzyski, Poland
🇫🇷Galderma Investigational Site 5140, Nice, France
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 105
- Registration Number
- NCT04921345
- Locations
- 🇵🇱
Galderma Investigational Site #6261, Wrocław, Poland
🇺🇸Galderma Investigational Site #8560, West Bloomfield, Michigan, United States
🇺🇸Galderma Investigational Site #9930, Vista, California, United States
A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 17
- Registration Number
- NCT04562116
- Locations
- 🇧🇬
5952 Galderma Investigational Site, Sofia, Bulgaria
🇺🇸9954 Galderma Investigational Site, Hallandale Beach, Florida, United States
🇺🇸9923 Galderma Investigational Site, Miami, Florida, United States
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 274
- Registration Number
- NCT04501679
- Locations
- 🇨ðŸ‡
Galderma Investigational Site, Weinfelden, Switzerland
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 225
- Registration Number
- NCT04365387
- Locations
- 🇺🇸
Galderma Investigational Site (Site#8813), Los Angeles, California, United States
🇺🇸Galderma Investigational Site (Site#8786), Clearwater, Florida, United States
🇺🇸Galderma Investigational Site (Site#8792), Doral, Florida, United States
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 500
- Registration Number
- NCT04204616
- Locations
- 🇺🇸
Galderma Investigational Galderma Investigational Site, Springville, Utah, United States
🇺🇸Galderma I Galderma Investigational Site, Lake Bluff, Illinois, United States
🇩🇪Galderme Investigational Site, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.